Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2025
DOI: 10.1016/j.eimce.2024.04.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2025. Verfasst von Eduardo Aparicio-Minguijón und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University Hospital '12 de Octubre', Spain. Electronic address: edu.ap93@gmail.com. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Endocarditis, Bacterial, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: This study aimed to evaluate the effectiveness of dalbavancin as sequential therapy in patients with infective endocarditis (IE) due to gram positive bacteria (GPB) in a real-life heterogenous cohort with comorbid patients. METHODS: A single center retrospective cohort study including all patients with definite IE treated with dalbavancin between January 2017 and February 2022 was developed. A 6-month follow-up was performed. The main outcomes were clinical cure rate, clinical and microbiological relapse, 6-month mortality, and adverse effects (AEs) rate. RESULTS: The study included 61 IE episodes. The median age was 78.5 years (interquartile range [IQR] 63.2-85.2), 78.7% were male, with a median Charlson comorbidity index of 7 (IQR 4-9) points. Overall, 49.2% suffered native valve IE. The most common microorganism was Staphylococcus aureus (26.3%) followed by Enterococcus faecalis (21.3%). The median duration of initial antimicrobial therapy and dalbavancin therapy were 27 (IQR 20-34) and 14 days (IQR 14-28) respectively. The total reduction of hospitalization was 1090 days. The most frequent dosage was 1500mg of dalbavancin every 14 days (96.7%). An AE was detected in 8.2% of patients, only one (1.6%) was attributed to dalbavancin (infusion reaction). Clinical cure was achieved in 86.9% of patients. One patient (1.6%) with Enterococcus faecalis IE suffered relapse. The 6-month mortality was 11.5%, with only one IE-related death (1.6%). CONCLUSION: This study shows a high efficacy of dalbavancin in a heterogeneous real-world cohort of IE patients, with an excellent safety profile. Dalbavancin allowed a substantial reduction of in-hospital length of stay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University Hospital '12 de Octubre', Spain. Electronic address: edu.ap93@gmail.com.
- Department of Internal Medicine, University Hospital '12 de Octubre', Spain.
- Department of Microbiology, University Hospital '12 de Octubre', Spain.
- Department of Cardiology, University Hospital '12 de Octubre', Spain.
- Department of Pharmacy, University Hospital '12 de Octubre', Spain.
- Department of Cardiac Surgery, University Hospital '12 de Octubre', Spain.
Zitieren
APA
Aparicio-Minguijón, E., Boán, J., Terrón, A., Heredia, C., Puente, C., Pérez-Jacoiste Asín, A., Orellana, M. Á., Domínguez, L., Caro, J. M., López-Gude, M. J., Aguilar-Blanco, E. M., Eixerés-Esteve, A., & López-Medrano, F. (2025). Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2024.04.012
Vancouver
Aparicio-Minguijón E, Boán J, Terrón A, Heredia C, Puente C, Pérez-Jacoiste Asín A, et al. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients. Enfermedades infecciosas y microbiologia clinica (English ed.). 2025. doi:10.1016/j.eimce.2024.04.012
BibTeX
@article{AparicioMinguijn2025,
author = {Aparicio-Minguijón, Eduardo and Boán, Jorge and Terrón, Antonio and Heredia, Carlos and Puente, Cristina and Pérez-Jacoiste Asín, Asunción and Orellana, M Ángeles and Domínguez, Laura and Caro, José Manuel and López-Gude, M Jesús and Aguilar-Blanco, Eva María and Eixerés-Esteve, Andrea and López-Medrano, Francisco},
title = {Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2025},
doi = {10.1016/j.eimce.2024.04.012}
}
EUVIMED